Illumina (NASDAQ:ILMN) and Prenetics Global (NASDAQ:PRE) Head to Head Survey

Prenetics Global (NASDAQ:PRE) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Prenetics Global and Illumina, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	0	0	1	0	3.00
Illumina	2	11	8	0	2.29

Prenetics Global currently has a consensus price target of $9.00, indicating a potential upside of 51.01%. Illumina has a consensus price target of $157.62, indicating a potential upside of 47.75%. Given Prenetics Global’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Prenetics Global is more favorable than Illumina.

Insider and Institutional Ownership

25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 0.2% of Illumina shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Prenetics Global and Illumina’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-282.96%	-10.76%	-8.79%
Illumina	-28.71%	2.31%	1.31%

Valuation & Earnings

This table compares Prenetics Global and Illumina’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$21.74 million	2.51	-$62.72 million	($4.45)	-1.34
Illumina	$4.50 billion	3.77	-$1.16 billion	($8.15)	-13.09

Prenetics Global has higher earnings, but lower revenue than Illumina. Illumina is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Prenetics Global has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.

Summary

Illumina beats Prenetics Global on 9 of the 14 factors compared between the two stocks.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.

About Illumina

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.